Current and emerging treatment strategies for the treatment of actinic keratosis

References

• MarksRJolleyDLecstasSFoleyPThe role of childhood exposure to sunlight in the development of solar keratoses and nonmelanocytic skin cancerMed J Aust199015262662296232
   PubMed Web of Science ®Google Scholar
• DrakeLACeilleyRICornelisonRLGuidelines of care for actinic keratosesJ Am Acad Dermatol19953295987529779
   PubMedGoogle Scholar
• CohenJLActinic keratosis treatment as a key component of prevalence strategies for nonmelanoma skin cancerJ Clin Aest Dermatol2010363944
   PubMedGoogle Scholar
• WarinoLTusaMCamachoFFrequency and cost of actinic keratosis treatmentDermatol Surg2006321045104916918567
   PubMed Web of Science ®Google Scholar
• BrashDERudolphJASimonJAA role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinomaProc Natl Acad Sci U S A19918810124101281946433
   PubMed Web of Science ®Google Scholar
• SilapuntSGoldbergLHAlamMTopical and light-based treatments for actinic keratosesSemn Cutan Med Surg2003223162170
   Web of Science ®Google Scholar
• CriscioneVDWeinstockMANaylorMFActinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs topical tretinoin chemoprevention trialCancer2009115112523253019382202
   PubMed Web of Science ®Google Scholar
• HurwitzRMMongerLESolar keratosis: an evolving squamous cell carcinoma. Benign or malignant?Dermatol Surg19952121847894943
   PubMed Web of Science ®Google Scholar
• LubritzRRSmolewskiSACryosurgery cure rate of actinic keratosesJ Am Acad Dermatol1982756316327142470
   PubMed Web of Science ®Google Scholar
• FeldmanSRFleischerABJrWillifordPMJorizzoJLDestructive procedures are the standard of care for treatment of actinic keratosesJ Am Acad Dermatol199940143479922011
   PubMed Web of Science ®Google Scholar
• WitheilerDDLawrenceNCoxSECockerellCJFreemenRGLong-term efficacy and safety of Jessner’s solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratosesDermatol Surg19972331911969145962
   PubMed Web of Science ®Google Scholar
• TrimasSJEllisDAFMetzRDThe carbon dioxide laser: an alternative for the treatment of actinically damaged skinDermatol Surg1997238858899357496
   PubMed Web of Science ®Google Scholar
• WollinaUKonradHKaramfilovTTreatment of common warts and actinic keratoses by Er:Yag laserJ Cutan Las Ther200136366
   PubMedGoogle Scholar
• FalksonGSchulzEJSkin changes in patients treated with 5-fluorouracilBr J Dermatol19627422923613891467
   PubMed Web of Science ®Google Scholar
• MenterAVamvakiasGJorizzoJOne-week treatment with once-daily fluorouracil cream 0.5% in participants with actinic keratosesCutis20088150951618666394
   PubMed Web of Science ®Google Scholar
• EaglsteinWHWeinsteinGDFrostPFluorouracil: mechanism of action in human skin and actinic keratoses. I. Effect on DNA synthesis in vivoArch Dermatol19701011321395413250
   PubMedGoogle Scholar
• KurwaHAYong-GeeSASeedPTMarkeyACBarlowRJA randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratosesJ Am Acad Dermatol19994141441810459115
   PubMed Web of Science ®Google Scholar
• JohnsonMRHageboutrosAWangKLife-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluoruracilClin Canc Res1999520062011
   PubMed Web of Science ®Google Scholar
• PearlmanDLWeekly pulse dosing: effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratosesJ Am Acad Dermatol1991256656671791225
   PubMed Web of Science ®Google Scholar
• EpsteinEDoes intermittent “pulse” topical 5-fluorouracil therapy allow destruction of actinic keratoses without significant inflammation?J Am Acad Dermatol19983877809448209
   PubMed Web of Science ®Google Scholar
• JuryCSRamraka-JonesVSGudiVHerdRMA randomized trial of topical 5% 5-fluorouracil in the treatment of actinic keratoses comparing daily with weekly treatmentBr J Dermatol200515380881016181465
   PubMed Web of Science ®Google Scholar
• ChadawarVShajiJMicrosponge delivery systemCanc Drug Deliv20074123129
   Google Scholar
• SimmondsWLDouble-blind investigation comparing a 1% vs 5% 5-fluorouracil topical cream in patients with multiple actinic keratosesCutis197312615617
   Google Scholar
• LovenKSteinLFurstKLevySEvaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosisClin Ther200224990100012117087
   PubMed Web of Science ®Google Scholar
• WeissJMenterAHeviaOEffective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeksCutis200270Suppl 2222912353677
   PubMed Web of Science ®Google Scholar
• MerkHFTopical diclofenac in the treatment of actinic keratosesInt J Dermatol200746121817214714
   PubMed Web of Science ®Google Scholar
• WeinbergJMTopical therapy for actinic keratoses: current and evolving therapiesRev Rec Clin Trials200615360
   PubMedGoogle Scholar
• RiversJKMcLeanDIAn open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratosesArch Dermatol1997133123912429382562
   PubMed Web of Science ®Google Scholar
• WolfJEJrTaylorJRTschenEKangSTopical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratosesInt J Dermatol20014070971311737438
   PubMed Web of Science ®Google Scholar
• RiversJKArletteJShearNTopical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gelBr J Dermatol20021469410011841372
   PubMed Web of Science ®Google Scholar
• BerlinJMRigelDSDiclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgeryJ Drug Dermatol20087669673
   PubMed Web of Science ®Google Scholar
• IfnerAKlugSJGarbeCThe prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosppressed individuals identifies high-risk genital types as possible risk factorsCancer Res200363217515751914612553
   PubMed Web of Science ®Google Scholar
• GaspariAAMechanism of action and otherpotential roles of an immune response modifierCutis200779SupplS36S45
   Google Scholar
• NewmanMDWeinbergJMTopical therapy in the treatment of actinic keratosis and basal cell carcinomaCutis200779182817508492
   PubMed Web of Science ®Google Scholar
• MeyerTNindlISchmookTInduction of apoptosis by Toll-like receptor-7 agonist in tissue culturesBr J Dermatol200314991414616338
   PubMed Web of Science ®Google Scholar
• TorresAStoreyLAndersMImmune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% creamJ Transl Med20075717257431
   PubMed Web of Science ®Google Scholar
• StockflethEMeyerTBenninghoffBChristophersESuccessful treatment of actinic keratosis with imiquimod cream 5%: a report of six casesBr J Dermatol20011441050105311359396
   PubMed Web of Science ®Google Scholar
• KormanNMoyRLingMDosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trialsArch Dermatol200514146747315837864
   PubMed Web of Science ®Google Scholar
• SwansonNAbramovitsWBermanBImiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cyclesJ Am Acad Dermatol201062458259020133013
   PubMed Web of Science ®Google Scholar
• HankeCWBeerKRStockflethEImquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cyclesJ Am Acad Dermatol201062457358120133012
   PubMed Web of Science ®Google Scholar
• OgbourneSMSuhbierAJonesBAntitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell deathCancer Res2004642833283915087400
   PubMed Web of Science ®Google Scholar
• ChallacombeJMSuhbierAParsonsPGNeutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelateJ Immunol20061778123813217114487
   PubMed Web of Science ®Google Scholar
• SillerGGebauerKWellburnPKatsamasJOgbourneSMPEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa studyAust J Dermatol2009501622
   PubMed Web of Science ®Google Scholar
• AndersonLSchmiederGJWerschlerWPRandomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosisJ Am Acad Dermatol20096093494319467365
   PubMed Web of Science ®Google Scholar
• GoldMHPhotodynamic therapy: indications and treatmentAesthetic Surg J2008285545552
   Google Scholar
• PengQWarloeTBergK5-Aminolevulinic acid-based photodynamic therapy – clinical research and future challengesCancer199779228223089191516
   PubMed Web of Science ®Google Scholar
• KennedyJCPottierRHProssDCPhotodynamic therapy with endogenous protoporphyrin IX: Basic principles and present clinical experienceJ Photochem Photobiol19906143148
   Web of Science ®Google Scholar
• JeffesEWMcCulloughJLWeinsteinGDExploring a new option in topical AK therapySkin Aging2001247
   Google Scholar
• PiacquadioDJChenDMFarberHFPhotodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalpArch Dermatol2004140414614732659
   PubMed Web of Science ®Google Scholar
• MoloneyFJCollinsPRandomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosesBr J Derm 2071578791
   Web of Science ®Google Scholar
• KurwaHAYoung-GeeSASeedPTMarkeyACBarlowRJA randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratosesJ Am Acad Dermatol19994141441810459115
   PubMed Web of Science ®Google Scholar